Does cortisol raise hepatic glucose output and reduce insulin sensitivity, causing higher fasting insulin even when HbA1c is normal?

A comprehensive assessment of clinical and mechanistic evidence supports the claim that cortisol increases hepatic glucose output and reduces insulin sensitivity, leading to compensatory hyperinsulinemia even when long-term glucose markers like HbA1c appear normal.

Mechanistic explanations

Cortisol acts as a potent modulator of glucose metabolism through several direct and indirect pathways:

• Hepatic Glucose Production: Cortisol binds to glucocorticoid receptors (GR) in the liver, stimulating the transcription of rate-limiting gluconeogenic enzymes, specifically PEPCK (PCK1) and G6Pase (G6PC). This increases the liver's production and release of glucose into the bloodstream.
• Peripheral Insulin Resistance: In skeletal muscle and adipose tissue, cortisol impairs the IRS-1/PI3K/Akt signaling pathway. This disruption prevents GLUT4 glucose transporters from moving to the cell surface, significantly reducing the amount of glucose these tissues can clear from circulation.
• Lipid Metabolism: Cortisol promotes lipolysis in adipose tissue, releasing free fatty acids (FFAs) into the blood. Elevated FFAs further interfere with insulin signaling, exacerbating systemic insulin resistance.

Clinical evidence and biomarkers

The relationship between cortisol and insulin levels is well-documented in clinical research:

• Compensatory Hyperinsulinemia: When cortisol reduces insulin sensitivity, the pancreas compensates by secreting more insulin to maintain glycemic control. This results in elevated fasting insulin levels even if fasting glucose remains within a standard range.
• HbA1c Limitations: HbA1c measures average blood glucose over 2-3 months. In early or subclinical metabolic dysfunction driven by cortisol, compensatory hyperinsulinemia can effectively keep blood glucose low enough to yield a "normal" HbA1c (<5.7%), thereby masking underlying insulin resistance.
• Study Findings: In large cohorts like the Jackson Heart Study, higher morning cortisol levels were significantly associated with increased HOMA-IR (a measure of insulin resistance). Studies using isotopic tracers have quantified that cortisol elevations can increase hepatic glucose release by nearly 75% (e.g., from 1.5 to 2.6 mmol/kg).

Clinical implications for older adults

For individuals in their 70s, these metabolic shifts are particularly relevant:

• Age-Related Sensitivity: Aging is naturally associated with decreased insulin sensitivity and a higher likelihood of compensatory hyperinsulinemia. Cortisol dysregulation (e.g., due to stress, sleep disruption, or chronic inflammation) can accelerate this process.
• Diagnostic Gap: Relying solely on HbA1c may lead to a "false sense of security" in patients with high cortisol levels, as it does not reflect the excessive insulin production required to maintain those glucose levels. Fasting insulin and HOMA-IR provide a more complete picture of metabolic health in this context.

Bottom line

Cortisol elevates fasting insulin by stimulating hepatic glucose production and blocking peripheral glucose uptake. Because the body compensates by producing more insulin to keep blood sugar stable, HbA1c often remains normal even as underlying insulin resistance and hyperinsulinemia progress.